Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arlene B Chapman

Showing results (41-50 of 220) with videos related to

Pageof 22
Sort By:
American Journal of Nephrology|March 23, 2007
Controversies in renal artery stenosis: a review by the American Society of Nephrology Advisory Group on HypertensionAdeera Levin, Stuart Linas, Friedrich C Luft, et al.
Physiological Genomics|July 9, 2009
Kininogen gene (KNG) variation has a consistent effect on aldosterone response to antihypertensive drug therapy: the GERA studyMaja Barbalic, Gary L Schwartz, Arlene B Chapman, et al.
American Journal of Hypertension|April 18, 2013
The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertensionGary L Schwartz, Kent Bailey, Arlene B Chapman, et al.
Plos One|January 28, 2015
A novel simple method for determining CYP2D6 gene copy number and identifying allele(s) with duplication/multiplicationTaimour Langaee, Issam Hamadeh, Arlene B Chapman, et al.
Kidney International Reports|December 23, 2017
Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4Olivier Devuyst, Arlene B Chapman, Susan E Shoaf, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 4, 2002
Reproducibility of blood pressure response to hydrochlorothiazideJavier D Finkielman, Gary L Schwartz, Arlene B Chapman, et al.
Journal of Clinical Pharmacology|February 21, 2017
Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 TrialSusan E Shoaf, Arlene B Chapman, Vicente E Torres, et al.
Kidney360|June 16, 2025
Transitional Care Units in the United States: A Model for Improving Dialysis CareLouis G Baeseman, Samantha Gunning, Bharathi V Reddy, et al.
Clinical Chemistry|October 31, 2002
Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratioGary L Schwartz, Arlene B Chapman, Eric Boerwinkle, et al.
American Journal of Hypertension|March 31, 2005
Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazideJavier Daniel Finkielman, Gary L Schwartz, Arlene B Chapman, et al.
Pageof 22

Showing results (41-50 of 220) with videos related to

Sort By:
Pageof 22
American Journal of Nephrology|March 23, 2007
Controversies in renal artery stenosis: a review by the American Society of Nephrology Advisory Group on HypertensionAdeera Levin, Stuart Linas, Friedrich C Luft, et al.
Physiological Genomics|July 9, 2009
Kininogen gene (KNG) variation has a consistent effect on aldosterone response to antihypertensive drug therapy: the GERA studyMaja Barbalic, Gary L Schwartz, Arlene B Chapman, et al.
American Journal of Hypertension|April 18, 2013
The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertensionGary L Schwartz, Kent Bailey, Arlene B Chapman, et al.
Plos One|January 28, 2015
A novel simple method for determining CYP2D6 gene copy number and identifying allele(s) with duplication/multiplicationTaimour Langaee, Issam Hamadeh, Arlene B Chapman, et al.
Kidney International Reports|December 23, 2017
Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4Olivier Devuyst, Arlene B Chapman, Susan E Shoaf, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 4, 2002
Reproducibility of blood pressure response to hydrochlorothiazideJavier D Finkielman, Gary L Schwartz, Arlene B Chapman, et al.
Journal of Clinical Pharmacology|February 21, 2017
Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 TrialSusan E Shoaf, Arlene B Chapman, Vicente E Torres, et al.
Kidney360|June 16, 2025
Transitional Care Units in the United States: A Model for Improving Dialysis CareLouis G Baeseman, Samantha Gunning, Bharathi V Reddy, et al.
Clinical Chemistry|October 31, 2002
Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratioGary L Schwartz, Arlene B Chapman, Eric Boerwinkle, et al.
American Journal of Hypertension|March 31, 2005
Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazideJavier Daniel Finkielman, Gary L Schwartz, Arlene B Chapman, et al.
Pageof 22